Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials.

Sebastian SchneeweissRobert RitzelEdward B JudeTerry DexLydie Melas-MeltJulio Rosenstock

Published in: Diabetes, obesity & metabolism (2023)

iGlarLixi is a simple, well-tolerated, once-daily alternative for treatment advancement in older people with T2D that provides significant improvements in glycaemic control without increasing hypoglycaemia risk, thus reducing the treatment burden.

Keyphrases

type diabetes
physical activity
cardiovascular disease
systematic review
clinical trial
insulin resistance
adipose tissue
smoking cessation
open label
community dwelling
meta analyses